Healthcare firm secures investment for patient app

A digital healthcare business has secured a £650,000 investment from NPIF – Mercia Equity Finance, which is managed by Mercia and is part of the Northern Powerhouse Investment Fund.

The funding will allow Advanced Digital Innovation (ADI) to boost uptake of its flagship product, MyPathway. The system, which is used by a number of NHS Trusts, connects patients to their healthcare provider through a web browser or a mobile app.

John Eaglesham, CEO, said: “At ADI, we are committed to bringing the digital revolution to the NHS and its patients. MyPathway provides both sides with the control and choice that we take for granted in other services. The NHS is undergoing a digital transformation and MyPathway is uniquely positioned to deliver this change in a cost-effective manner.”

MyPathway provides digital triage, supports personalised rehabilitation programmes and allows clinicians to monitor patients’ progress and access patient-reported data and feedback.

ADI has been working with Sheffield Teaching Hospitals NHS Foundation Trust, North West Boroughs Healthcare NHS Foundation Trust and has recently won a further contract with NHS North East Essex CCG. The company has also carried out two successful clinical trials with the Hospital Clinic of Barcelona. It is now looking to sign up other Trusts across the UK. The investment will allow the company to build its sales and marketing team and further develop its product.

Jonathan Sharp, investment manager with Mercia, said: “MyPathway revolutionises the relationship between patients and healthcare providers, saving time and money and making the patient’s healthcare journey much easier to manage. The investment will allow ADI to drive sales growth and build awareness of the product in the healthcare market.”


'Healthcare firm secures investment for patient app' has no comments

Be the first to comment this post!

Would you like to share your thoughts?

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

© 2019 Rapid Life Sciences Ltd, a Rapid News Group Company. All Rights Reserved.

Privacy policy

Terms and conditions